Search

Your search keyword '"Pan, Henry Y.C."' showing total 11 results
Start Over Author "Pan, Henry Y.C."
11 results on '"Pan, Henry Y.C."'

1. RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned

Author

Mottrie, Alex, Fuller, Andrew, Mottaran, Angelo, Challacombe, Ben, Kua, Boon, Metcalfe, Charles, Wagner, Christian, Dubey, Deepak, Gomez Sancha, Fernando, Bruyère, Franck, Gautam, Gagan, Pooleri, Ginil K., Bozzini, Giorgio, Lau, Howard, Thyer, Isaac, Teoh, Jeremy, Vass, Justin, Vivian, Justin, McDermott, Kara, Winter, Mathew, Ragavan, Narasimhan, Campbell, Nicholas, Harke, Nina N., Richard, Patrick O., Teloken, Patrick, Dekuyper, Peter, Sutherland, Peter, Ahlawat, Rajesh, Nair, Rajesh, Pemberton, Richard, Catterwell, Rick, Oomen, Robert J.A., Weston, Robin, Moritz, Rudolf, Krishnappa, Raghunath S., Leslie, Scott, Van Appledorn, Scott, Yuvaraja, T.B., Meert, Thibault, Dujardin, Thierry, Gross, Tobias, Walton, Tom, Huang, William C., Caumartin, Yves, Agarwal, Dinesh K., Mulholland, Clancy, Koye, Digsu N., Sathianathen, Niranjan, Yao, Henry, Dundee, Philip, Moon, Daniel, Furrer, Marc, Giudice, Christina, Wang, Wayland, Simpson, Julie A., Kearsley, Jamie, Norris, Briony, Zargar, Homi, Pan, Henry Y.C., Agarwal, Ashwin, Lawrentschuk, Nathan, and Corcoran, Niall M.

Published
2023
Full Text
View/download PDF

2. Protocol for CAMUS Delphi Study: A Consensus on Comprehensive Reporting and Grading of Complications After Urological Surgery

Author

Soliman, Christopher, Mulholland, Clancy J., Santaguida, Pasqualina, Sathianathen, Niranjan J., Lawrentschuk, Nathan, Giannarini, Gianluca, Wuethrich, Patrick Y., Loeffel, Lukas M., Cacciamani, Giovanni E., Pan, Henry Y.C., Nair, Rajesh, Cumberbatch, Marcus G., Riedel, Bernhard, Thomas, Benjamin C., Kearsley, Jamie, Corcoran, Niall, Dundee, Philip, and Furrer, Marc A.

Published
2022
Full Text
View/download PDF

3. Corrigendum to “RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned” [Eur. Urol. Open Sci. 54 (2023) 33–42]

Author

Agarwal, Dinesh K., primary, Mulholland, Clancy, additional, Koye, Digsu N., additional, Sathianathen, Niranjan, additional, Yao, Henry, additional, Dundee, Philip, additional, Moon, Daniel, additional, Furrer, Marc, additional, Giudice, Christina, additional, Wang, Wayland, additional, Simpson, Julie A., additional, Kearsley, Jamie, additional, Norris, Briony, additional, Zargar, Homi, additional, Pan, Henry Y.C., additional, Mottrie, Alex, additional, Fuller, Andrew, additional, Mottaran, Angelo, additional, Challacombe, Ben, additional, Kua, Boon, additional, Metcalfe, Charles, additional, Wagner, Christian, additional, Dubey, Deepak, additional, Gomez Sancha, Fernando, additional, Bruyère, Franck, additional, Gautam, Gagan, additional, Pooleri, Ginil K., additional, Bozzini, Giorgio, additional, Lau, Howard, additional, Thyer, Isaac, additional, Teoh, Jeremy, additional, Vass, Justin, additional, Vivian, Justin, additional, McDermott, Kara, additional, Winter, Mathew, additional, Ragavan, Narasimhan, additional, Campbell, Nicholas, additional, Harke, Nina N., additional, Richard, Patrick O., additional, Teloken, Patrick, additional, Dekuyper, Peter, additional, Sutherland, Peter, additional, Ahlawat, Rajesh, additional, Nair, Rajesh, additional, Pemberton, Richard, additional, Catterwell, Rick, additional, Oomen, Robert J.A., additional, Weston, Robin, additional, Moritz, Rudolf, additional, Krishnappa, Raghunath S., additional, Leslie, Scott, additional, Van Appledorn, Scott, additional, Yuvaraja, T.B., additional, Meert, Thibault, additional, Dujardin, Thierry, additional, Gross, Tobias, additional, Walton, Tom, additional, Huang, William C., additional, Caumartin, Yves, additional, Agarwal, Ashwin, additional, Lawrentschuk, Nathan, additional, and Corcoran, Niall M., additional

Published
2024
Full Text
View/download PDF

4. Comparison of Robotic vs Open Cystectomy: A Systematic Review

Author

Sathianathen, Niranjan J., primary, Pan, Henry Y.C., additional, Furrer, Marc, additional, Thomas, Benjamin, additional, Dundee, Philip, additional, Corcoran, Niall, additional, Weight, Christopher J., additional, Konety, Badrinath, additional, Nair, Rajesh, additional, and Lawrentschuk, Nathan, additional

Published
2023
Full Text
View/download PDF

5. RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned

Author

Agarwal, Dinesh K., primary, Mulholland, Clancy, additional, Koye, Digsu N., additional, Sathianathen, Niranjan, additional, Yao, Henry, additional, Dundee, Philip, additional, Moon, Daniel, additional, Furrer, Marc, additional, Giudice, Christina, additional, Wang, Wayland, additional, Simpson, Julie A., additional, Kearsley, Jamie, additional, Norris, Briony, additional, Zargar, Homi, additional, Pan, Henry Y.C., additional, Agarwal, Ashwin, additional, Lawrentschuk, Nathan, additional, Corcoran, Niall M., additional, Mottrie, Alex, additional, Fuller, Andrew, additional, Mottaran, Angelo, additional, Challacombe, Ben, additional, Kua, Boon, additional, Metcalfe, Charles, additional, Wagner, Christian, additional, Dubey, Deepak, additional, Gomez Sancha, Fernando, additional, Bruyère, Franck, additional, Gautam, Gagan, additional, Pooleri, Ginil K., additional, Bozzini, Giorgio, additional, Lau, Howard, additional, Thyer, Isaac, additional, Teoh, Jeremy, additional, Vass, Justin, additional, Vivian, Justin, additional, McDermott, Kara, additional, Winter, Mathew, additional, Ragavan, Narasimhan, additional, Campbell, Nicholas, additional, Harke, Nina N., additional, Richard, Patrick O., additional, Teloken, Patrick, additional, Dekuyper, Peter, additional, Sutherland, Peter, additional, Ahlawat, Rajesh, additional, Nair, Rajesh, additional, Pemberton, Richard, additional, Catterwell, Rick, additional, Oomen, Robert J.A., additional, Weston, Robin, additional, Moritz, Rudolf, additional, Krishnappa, Raghunath S., additional, Leslie, Scott, additional, Van Appledorn, Scott, additional, Yuvaraja, T.B., additional, Meert, Thibault, additional, Dujardin, Thierry, additional, Gross, Tobias, additional, Walton, Tom, additional, Huang, William C., additional, and Caumartin, Yves, additional

Published
2023
Full Text
View/download PDF

7. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis.

Author

Sathianathen, Niranjan J., Pan, Henry Y.C., Lawrentschuk, Nathan, Siva, Shankar, Azad, Arun A., Tran, Ben, Bolton, Damien, and Murphy, Declan G.

Subjects
*CASTRATION-resistant prostate cancer, *PROSTATE cancer, *ANDROGEN receptors, *PROSTATE cancer patients, *METASTASIS, *PROGRESSION-free survival
Abstract

Introduction: There have been a growing number of treatment options available for men with metastatic castration-sensitive prostate cancer. Not only have newer agents entered the clinical landscape, there is a trend toward treatment intensification by combining multiple agents simultaneously. We aim to assess the best contemporary treatment option for men with mCSPC.Materials and Methods: We perform an updated systematic review and network meta-analysis of randomized control trials that evaluated systemic therapies in men with castration-sensitive prostate cancer. We searched multiple databases up to April 2022. We included all randomized trials assessing the effect of systemic agents. We performed subgroup analyses based on disease volume and timing of presentation. Statistical analysis was performed with Bayesian methods.Results: We found 10 eligible trials with 10,065 patients who were included in this analysis. Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival. In the sensitivity analysis, the respective hazard ratios for triplet therapy was HR 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT and 0.77 (95%CI 0.65-0.91) compared to androgen receptor pathway inhibitors+ADT combinations. It was estimated that there was 96% chance that one of the triplet therapy combinations were the best treatment option from an OS perspective. Triplet therapy also improved progression-free survival. These benefits were pronounced in men with high-volume disease burden and those with de novo metastatic disease.Conclusion: The finding suggest that triplet therapy is likely the most efficacious available option in men with metastatic, castration-sensitive prostate cancer, especially in those with high-volume disease burden. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care

Author

Soliman, Christopher, primary, Sathianathen, Niranjan J., additional, Giannarini, Gianluca, additional, Wuethrich, Patrick Y., additional, Pan, Henry Y.C., additional, Thomas, Benjamin C., additional, Dundee, Philip, additional, Cumberbatch, Marcus G., additional, Nair, Rajesh, additional, Lawrentschuk, Nathan, additional, and Furrer, Marc A., additional

Published
2022
Full Text
View/download PDF

10. Detection and localisation of primary prostate cancer using 68 gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology

Author

Kalapara, Arveen A., primary, Nzenza, Tatenda, additional, Pan, Henry Y.C., additional, Ballok, Zita, additional, Ramdave, Shakher, additional, O'Sullivan, Richard, additional, Ryan, Andrew, additional, Cherk, Martin, additional, Hofman, Michael S., additional, Konety, Badrinath R., additional, Lawrentschuk, Nathan, additional, Bolton, Damien, additional, Murphy, Declan G., additional, Grummet, Jeremy P., additional, and Frydenberg, Mark, additional

Published
2020
Full Text
View/download PDF

11. Detection and localisation of primary prostate cancer using 68gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology

Author

Kalapara, Arveen A., Nzenza, Tatenda, Pan, Henry Y.C., Ballok, Zita, Ramdave, Shakher, O'Sullivan, Richard, Ryan, Andrew, Cherk, Martin, Hofman, Michael S., Konety, Badrinath R., Lawrentschuk, Nathan, Bolton, Damien, Murphy, Declan G., Grummet, Jeremy P., and Frydenberg, Mark

Subjects
POSITRON emission tomography computed tomography, MAGNETIC resonance imaging, PROSTATE-specific antigen, PROSTATE cancer, COMPUTED tomography, ENDORECTAL ultrasonography, PROSTATECTOMY
Abstract

Objective: To compare the accuracy of 68gallium prostate‐specific membrane antigen positron emission tomography/computed tomography (68Ga‐PSMA PET/CT) with multiparametric MRI (mpMRI) in detecting and localising primary prostate cancer when compared with radical prostatectomy (RP) specimen pathology. Patients and methods: Retrospective review of men who underwent 68Ga‐PSMA PET/CT and mpMRI for primary prostate cancer before RP across four centres between 2015 and 2018. Patients undergoing imaging for recurrent disease or before non‐surgical treatment were excluded. We defined pathological index tumour as the lesion with highest International Society of Urological Pathology Grade Group (GG) on RP specimen pathology. Our primary outcomes were rates of accurate detection and localisation of RP specimen pathology index tumour using 68Ga‐PSMA PET/CT or mpMRI. We defined tumour detection as imaging lesion corresponding with RP specimen tumour on any imaging plane, and localisation as imaging lesion matching RP specimen index tumour in all sagittal, axial, and coronal planes. Secondary outcomes included localisation of clinically significant and transition zone (TZ) index tumours. We defined clinically significant disease as GG 3–5. We used descriptive statistics and the Mann–Whitney U‐test to define and compare demographic and pathological characteristics between detected, missed and localised tumours using either imaging modality. We used the McNemar test to compare detection and localisation rates using 68Ga‐PSMA PET/CT and mpMRI. Results: In all, 205 men were included in our analysis, including 133 with clinically significant disease. There was no significant difference between 68Ga‐PSMA PET/CT and mpMRI in the detection of any tumour (94% vs 95%, P > 0.9). There was also no significant difference between localisation of all index tumours (91% vs 89%, P = 0.47), clinically significant index tumours (96% vs 91%, P = 0.15) or TZ tumours (85% vs 80%, P > 0.9) using 68Ga‐PSMA PET/CT and mpMRI. Limitations include retrospective study design and non‐central review of imaging and pathology. Conclusion: We found no significant difference in the detection or localisation of primary prostate cancer between 68Ga‐PSMA PET/CT and mpMRI. Further prospective studies are required to evaluate a combined PET/MRI model in minimising tumours missed by either modality. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results